A new study reveals the rising burden of liver cancer, highlighting the significant impact of metabolic risk factors like obesity, in addition to viral hepatitis.

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Liver cancer is a leading cause of cancer-related deaths worldwide, with distinct geographic patterns in its incidence.

The Series A funding round by the start-up, co-founded by executives of Aiolos Bio, the biotech that was sold to GSK last ...

-- Stick with investing in the AI revolution, the space revolution and the autonomous-vehicle revolution, as they will radically change the world for the better and are among the most likely trends to ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

The experts note that mixing fresh water with salt water could reduce acidity and enhance nutrient absorption in the ...

Dr. Kenneth Thorpe shares more about the new study that links weight loss to cost savings ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care ...